Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to compare the effectiveness of myo-inositol (MYO) and metformin, in monotherapy or in association with recombinant follicle stimulating hormone (r-FSH), in the treatment of menstrual irregularities, chronic anovulation, and female infertility in patients with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: One hundred twenty patients were randomly treated with metformin 1500 mg/day orally (n = 60), or 4 g MYO plus 400 microg folic acid daily (n = 60), continuously. If no pregnancy occurred, r-FSH (37.5 units/day) was added to the treatment for a maximum of three attempts. RESULTS: Fifty percent of the patients who assumed metformin restored spontaneous ovulation, 18.3% of these obtained pregnancy. The remaining 42 patients were treated with metformin plus r-FSH. Pregnancy occurred in a total of 11 women (26.1%). The total pregnancy rate was 36.6%. Sixty-five percent of the patients treated with MYO plus folic acid restored spontaneous ovulation activity, 30% of these obtained pregnancy. The remaining 38 patients were treated with MYO, folic acid plus r-FSH. Pregnancy occurred in a total of 11 women (28.9%). The total pregnancy rate was 48.4%. CONCLUSIONS: Both metformin and MYO, can be considered as first line treatment for restoring normal menstrual cycles in most patients with PCOS, even if MYO treatment seems to be more effective than metformin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These studies used co-interventions of fertility treatment, either ovulation induction with letrozole (49), gonadotropin (50), or gonadotropin and intrauterine insemination (46) or in vitro fertilization (IVF) with or without intracytoplasmic sperm injection (ICSI) (25, 27, 40, 47, 48, 51, 55).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [50]
In the citing paper
“Ten studies specifically enrolled women with PCOS who also had infertility (25, 27, 40, 46-51, 55, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [50]
In the citing paper
“Twelve used metformin at doses of 1000 mg to 2000 mg daily alone or in combination with FA as a comparator (26, 28, 30, 33, 39, 41, 42, 49-54, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [50]
In the citing paper
“Reproductive outcomes including resumption of normal menstrual cycles (Fig. 5N, 3 studies) (26, 33, 51) or rate of ovulation (Fig. 5O, 2 studies)(49, 50) did not differ between groups.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [50]
In the citing paper
“Four trials (n = 420) (26, 49-51) reported no differences in clinical pregnancy rate, and 1 (n = 120) (50) reported no difference in miscarriage rate between MI and metformin.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [50]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS [24,25].”
RetractedRETRACTED: Treatment of hirsutism with myo-inositol: a prospective clinical study
Minozzi, M., D'Andrea, G., & Unfer, V. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60248-9 · Cited by 56 · cited 1×
“…DCI and has positive effects on hyperinsulinemic, PCOS women in reproductive age, both on spontaneous ovulation and metabolic parameters [13,24–26, 31 Our data support the hypothesis of a primary role of both metformin and MYO as first-line therapies for restoring a spontaneous ovulation in women…”
RetractedThe Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 1×
“Interestingly, both obese and lean women with PCOS manifest insulin resistance independent of fat mass [11].”
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Franks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 1×
“The outcome of the use of insulin-sensitising agents in monotherapy or in association with clomiphene citrate for ovulation induction is still debated in term of increasing rate of both spontaneous ovulation and pregnancy [18–23].”
Menstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 2×
“Many interventional studies have demonstrated a positive [20].”
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313 · cited 1×
“In conclusion, insulin sentitiser agents, both metformin and MYO, can be considered first-line treatment in most patients with PCOS, for restoring normal mentrual cycles [33].”
Cibula, D. (2000) · Human Reproduction · doi:10.1093/humrep/15.4.785 · Cited by 267 · cited 1×
“In the long term, PCOS is associated with an increased risk of developing hypertension, dyslipidemia, impaired glucose tolerance or type 2 diabetes [6,7] and may also confer an increased risk of cardiovascular disease [8–10].”
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221 · cited 2×
“…to DCI and has positive effects on hyperinsulinemic, PCOS women in reproductive age, both on spontaneous ovulation and metabolic parameters [13,24–26, 31 Our data support the hypothesis of a primary role of both metformin and MYO as first-line therapies for restoring a spontaneous ovulation…”
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188
Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction
Papaleo, E., Unfer, V., Baillargeon, J.-P., De Santis, L., Fusi, F., Brigante, C., Marelli, G., Cino, I., Redaelli, A., & Ferrari, A. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701672405 · Cited by 185 · cited 1×
“Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS [24,25].”
Chiu, T. T. Y., Rogers, M. S., Law, E. L. K., Briton-Jones, C. M., Cheung, L. P., & Haines, C. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1591 · Cited by 182 · cited 2×
“Inositol is correlated to oocyte maturity through Ca 2 þ signalling [17].”
Second Messengers of Insulin Action
Saltiel, A. R. (1990) · Diabetes Care · doi:10.2337/diacare.13.3.244 · Cited by 148 · cited 1×
“…in PCOS have been extensively investigated, and it is evident that the major defect is a decrease in insulin sensitivity secondary to a post-binding abnormality in insulin receptor-mediated signal transduction, with a less substantial, but significant, decrease in insulin responsiveness [28–30].”
Altered D-Chiro-Inositol Urinary Clearance in Women With Polycystic Ovary Syndrome
Baillargeon, J.-P., Diamanti-Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., & Nestler, J. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1070 · Cited by 146 · cited 1×
“Indeed, a defect in tissue availability or altered metabolism of DCI or inositol phosphoglycan mediators have been found in women affected by PCOS and may contribute to their insulin resistance [15,16].”
Insulin Sensitizers for Polycystic Ovary Syndrome
BAILLARGEON, J.-P., IUORNO, M. J., & NESTLER, J. E. (2003) · Clinical Obstetrics and Gynecology · doi:10.1097/00003081-200306000-00011 · Cited by 132 · cited 2×
“In the long term, PCOS is associated with an increased risk of developing hypertension, dyslipidemia, impaired glucose tolerance or type 2 diabetes [6,7] and may also confer an increased risk of cardiovascular disease [8–10].”
Cheang, K. I., Baillargeon, J.-P., Essah, P. A., Ostlund, R. E., Apridonize, T., Islam, L., & Nestler, J. E. (2008) · Metabolism · doi:10.1016/j.metabol.2008.05.008 · Cited by 129 · cited 1×
“An inositol phosphoglycan molecule containing D-chiro-inositol (DCI) is known to have a role in activating enzymes that control glucose metabolism [14].”
Dermatologic Manifestations of Polycystic Ovary Syndrome
Lee, A. T., & Zane, L. T. (2007) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200708040-00003 · Cited by 110
Involvement of Inositol in Reproduction
Beemster, P., Groenen, P., & Steegers-Theunissen, R. (2002) · Nutrition Reviews · doi:10.1301/00296640260042748 · Cited by 106 · cited 1×
“MYO was approved as experimental treatment in consideration of the effects that belongs to B-vitamin group, and in the literature there are plenty of records for its use in patients with PCOS and its safety in reproduction [20,27].”
Metformin treatment is effective in obese teenage girls with PCOS
De Leo, V. (2006) · Human Reproduction · doi:10.1093/humrep/del185 · Cited by 101 · cited 1×
“Insulin sensitising compounds, such as metformin, pioglitazone and troglitazone have been proposed as putative treatments for hyperinsulinemia-induced dysfunction of ovarian response to endogenous gonadotropins to improve ovulation, menstrual cycles and hyperandrogenemia [6,12,13].”
Larner, J. (1988) · Diabetes · doi:10.2337/diab.37.3.262 · Cited by 97
Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective
Nestler, J. E. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.04.073 · Cited by 71 · cited 1×
“Trials of both metformin or MYO in monotherapy, followed by very low-dose r-FSH ovulation induction in case pregnancy is not achieved in a few months, are a reasonable approach, to reduce risk of ovarian hyperstimulation syndrome and multiple pregnancy [32].”
Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome
Cattrall, F. R., & Healy, D. L. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.05.005 · Cited by 61 · cited 1×
“In the long term, PCOS is associated with an increased risk of developing hypertension, dyslipidemia, impaired glucose tolerance or type 2 diabetes [6,7] and may also confer an increased risk of cardiovascular disease [8–10].”
Diagnostic Criteria for Polycystic Ovarian Syndrome
Broekmans, F. J., & Fauser, B. C. J. M. (2006) · Endocrine · doi:10.1385/endo:30:1:3 · Cited by 60 · cited 2×
“The association between insulin resistance, compensatory hyperinsulinemia and hyperandrogenism has provided insight into the pathogenesis of PCOS [4].”
Use of insulin sensitizers in polycystic ovarian syndrome.
Baillargeon, J. (2005) · PubMed · Cited by 46
Mediators of postreceptor action of insulin
Larner, J. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90653-8 · Cited by 42 · cited 1×
“…in PCOS have been extensively investigated, and it is evident that the major defect is a decrease in insulin sensitivity secondary to a post-binding abnormality in insulin receptor-mediated signal transduction, with a less substantial, but significant, decrease in insulin responsiveness [28–30].”
Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?
Cheang, K. I., & Nestler, J. E. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60928-5 · Cited by 37 · cited 1×
“The outcome of the use of insulin-sensitising agents in monotherapy or in association with clomiphene citrate for ovulation induction is still debated in term of increasing rate of both spontaneous ovulation and pregnancy [18–23].”
Ovulation induction in polycystic ovary syndrome—how do metformin and clomifene citrate compare?
Pesant, M.-H., & Baillargeon, J. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0529 · Cited by 8
Research works printed but not linked: 1
- 10.1016/j.bpobgyn.2004.05.005 · DOI
Cited by
Potential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 578
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
“metformin [36] and in four of these trials [20,22,35,36] the dosage of 4 g of MYO was used; in one trial [34] 2 g of MYO were used.”
MethodAntioxidants for female subfertility
Showell, M. G., Brown, J., Clarke, J., & Hart, R. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub2 · Cited by 184
Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Unfer, V., Nestler, J. E., Kamenov, Z. A., Prapas, N., & Facchinetti, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1849162 · Cited by 151
“[27] compared the effects of metformin (Glucophage , Merck Pharma) andMyo-Ins (Inofolic, LO.”
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach
Laganà, A. S., Garzon, S., Casarin, J., Franchi, M., & Ghezzi, F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.09.001 · Cited by 149
“The results were not statistically different, suggesting that treatment with MI or metformin plus folic acid are equally effective [47].”
Metadata
- Authors
- Raffone, E., Rizzo, P., & Benedetto, V.
- Affiliations
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT)
- Corresponding author
- Raffone, Emanuela
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2009-11-09
- Volume
- 26
- Issue
- 4
- Pages
- 275-280
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2150739827
- Semantic Scholar
- 49c52f76392dca4973a54b06baf398988524e85e
- Cited by
- 100
- References
- 32
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 7 · 2021: 9 · 2020: 10 · 2019: 7 · 2018: 11 · 2017: 11 · 2016: 4 · 2015: 1 · 2014: 4 · 2013: 5 · 2012: 2
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2026-06-16)
- Open access
- closed
- Locations
- Gynecological Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- polycystic ovary syndrome, myo-inositol, metformin, insulin sensitizers, recombinant FSH, ovulation induction, female infertility, anovulation, menstrual irregularity, pregnancy rate, folic acid
- MeSH terms
- Adult, Anovulation, Drug Therapy, Combination, Female, Fertility Agents, Female, Folic Acid, Follicle Stimulating Hormone, Humans, Hypoglycemic Agents, Infertility, Female, Inositol, Menstruation Disturbances, Metformin, Ovulation Induction, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Rate, Dietary Supplements, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.